Literature DB >> 33535473

Anti-NLRP3 Inflammasome Natural Compounds: An Update.

Baolong Liu1, Jiujiu Yu1.   

Abstract

The nucleotide-binding domain and leucine-rich repeat related (NLR) family, pyrin domain containing 3 (NLRP3) inflammasome is a multimeric protein complex that recognizes various danger or stress signals from pathogens, the host, and the environment, leading to activation of caspase-1 and inducing inflammatory responses. This pro-inflammatory protein complex plays critical roles in pathogenesis of a wide range of diseases including neurodegenerative diseases, autoinflammatory diseases, and metabolic disorders. Therefore, intensive efforts have been devoted to understanding its activation mechanisms and to searching for its specific inhibitors. Approximately forty natural compounds with anti-NLRP3 inflammasome properties have been identified. Here, we provide an update about new natural compounds that have been identified within the last three years to inhibit the NLRP3 inflammasome and offer an overview of the underlying molecular mechanisms of their anti-NLRP3 inflammasome activities.

Entities:  

Keywords:  NLRP3 inflammasome; inflammatory diseases; medicinal herbs; natural compounds

Year:  2021        PMID: 33535473      PMCID: PMC7912743          DOI: 10.3390/biomedicines9020136

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  126 in total

Review 1.  Multiple sclerosis - a review.

Authors:  R Dobson; G Giovannoni
Journal:  Eur J Neurol       Date:  2018-11-18       Impact factor: 6.089

Review 2.  Hypertensive Heart Disease and Obesity: A Review.

Authors:  L Joseph Saliba; Scott Maffett
Journal:  Heart Fail Clin       Date:  2019-08-07       Impact factor: 3.179

Review 3.  Inflammation, cancer, and targets of ginseng.

Authors:  Lorne J Hofseth; Michael J Wargovich
Journal:  J Nutr       Date:  2007-01       Impact factor: 4.798

4.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization.

Authors:  Veit Hornung; Franz Bauernfeind; Annett Halle; Eivind O Samstad; Hajime Kono; Kenneth L Rock; Katherine A Fitzgerald; Eicke Latz
Journal:  Nat Immunol       Date:  2008-07-11       Impact factor: 25.606

5.  In vivo anti-diabetic activity of derivatives of isoliquiritigenin and liquiritigenin.

Authors:  Rashmi Gaur; Kuldeep Singh Yadav; Ram Kishor Verma; Narayan Prasad Yadav; Rajendra Singh Bhakuni
Journal:  Phytomedicine       Date:  2013-11-19       Impact factor: 5.340

6.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

Authors:  Claus M Larsen; Mirjam Faulenbach; Allan Vaag; Aage Vølund; Jan A Ehses; Burkhardt Seifert; Thomas Mandrup-Poulsen; Marc Y Donath
Journal:  N Engl J Med       Date:  2007-04-12       Impact factor: 91.245

7.  Ginsenoside Rb1 and compound K improve insulin signaling and inhibit ER stress-associated NLRP3 inflammasome activation in adipose tissue.

Authors:  Weijie Chen; Junlian Wang; Yong Luo; Tao Wang; Xiaochun Li; Aiyun Li; Jia Li; Kang Liu; Baolin Liu
Journal:  J Ginseng Res       Date:  2015-11-27       Impact factor: 6.060

8.  Targeting ASC in NLRP3 inflammasome by caffeic acid phenethyl ester: a novel strategy to treat acute gout.

Authors:  Hye Eun Lee; Gabsik Yang; Nam Doo Kim; Seongkeun Jeong; Yunjin Jung; Jae Young Choi; Hyun Ho Park; Joo Young Lee
Journal:  Sci Rep       Date:  2016-12-09       Impact factor: 4.379

9.  Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies.

Authors:  Gaia Codolo; Nicoletta Plotegher; Tommaso Pozzobon; Marco Brucale; Isabella Tessari; Luigi Bubacco; Marina de Bernard
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

Review 10.  Natural Compounds as Regulators of NLRP3 Inflammasome-Mediated IL-1β Production.

Authors:  József Tőzsér; Szilvia Benkő
Journal:  Mediators Inflamm       Date:  2016-09-08       Impact factor: 4.711

View more
  3 in total

1.  In-vitro inhibition of NLRP3 inflammasome by 3,6-dihydroxyflavone (3,6-DHF): a therapeutic strategy for the treatment of chronic inflammatory and autoimmune diseases.

Authors:  Farheen Mansoor; Almas Jabeen; Syeda Farah Shah; Shabana U Simjee; Samina Bano; Shaheen Faizi
Journal:  Mol Cell Biochem       Date:  2022-08-11       Impact factor: 3.842

2.  Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial.

Authors:  Adel A Gomaa; Hamdy S Mohamed; Rasha B Abd-Ellatief; Mohamed A Gomaa; Doaa S Hammam
Journal:  Inflammopharmacology       Date:  2022-03-01       Impact factor: 4.473

Review 3.  A Selective Review and Virtual Screening Analysis of Natural Product Inhibitors of the NLRP3 Inflammasome.

Authors:  Sherihan El-Sayed; Sally Freeman; Richard A Bryce
Journal:  Molecules       Date:  2022-09-21       Impact factor: 4.927

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.